Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 1,601–1,700 of 2,517
Yu, Z. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i13.1979 · Cited by 16
“p53 protein had different domains for DNA binding, transactivation, and tetramerization functions[ 24 ,25].”
BackgroundExtrapolation of Radiation-Induced Cancer Risks from Nonhuman Experimental Systems to Humans
Mossman, K. L. (2006) · Health Physics · doi:10.1097/01.hp.0000223465.78404.c6 · Cited by 14
Where cancer meets calcium--p53 crosstalk with EF-hands.
Ikura, M., & Yap, K. L. (2000) · Nature Structural Biology · doi:10.1038/76721 · Cited by 14
Kristjuhan, A., & Maimets, T. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.827_a.x · Cited by 17
Kaneko, K., Kurahashi, T., Makino, R., Konishi, K., Ito, H., Katagiri, A., Kumekawa, Y., Hirayama, Y., Yoneyama, K., Kushima, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601965 · Cited by 14
“P-values less than 0.05 were considered to indicate significance.”
BackgroundInfluentialCohen, P. A., Hupp, T. R., Lane, D. P., & Daniels, D. A. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01603-8 · Cited by 14
p53 Unfolding Detected by CD but Not by Tryptophan Fluorescence
Nichols, N. M., & Matthews, K. S. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5764 · Cited by 14
Molecular Analysis of the p53 Gene in Pancreatic Adenocarcinoma
Li, Y., Bhuiyan, M., Vaitkevicius, V. K., et al. (1998) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199802000-00002 · Cited by 14
Knudsen, T. B. (1997) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-60445-4_8 · Cited by 17
Rehberger, P. A., Richter, K. H., Schwartz, D., Goldfinger, N., Oskato, R., Almog, N., Marks, F., & Rotter, V. (1997) · PubMed · Cited by 14
Klett, T., Stahlecker, J., Jaag, S., Masberg, B., Knappe, C., Lämmerhofer, M., Coles, M. P., Stehle, T., & Boeckler, F. M. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00414 · Cited by 15
Proteolytic cleavage of p53 mutants in response to mismatched DNA
Mee, T. R., Okorokov, A. L., Metcalfe, S. M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690679 · Cited by 13
“The central core domain of p53 (amino acids 102–292) can bind with sequence-specificity to DNA elements (Cho et al, 1994).”
BackgroundInfluentialLu, J., Yin, J., Dong, R., Yang, T., Yuan, L., ZANG, L., Xu, C., PENG, B., Zhao, J., & Du, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3952 · Cited by 13
Chen, B., Zhu, Y., Ye, S., & Zhang, R. (2018) · Journal of Structural Biology · doi:10.1016/j.jsb.2018.04.007 · Cited by 18
Sandoval, J. E., & Reich, N. O. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010827 · Cited by 16
“cancers, the majority of p53 mutations are missense mutations throughout the p53 DNAbinding domain (48-51).”
BackgroundInfluentialMorabito, F., Gentile, M., Monti, P., Recchia, A. G., Menichini, P., Skafi, M., Atrash, M., Luca, G. D., Bossio, S., Al‐Janazreh, H., et al. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1783239 · Cited by 14
GDF‐15: Diagnostic, prognostic, and therapeutic significance in glioblastoma multiforme
Segherlou, Z. H., Nouri‐Vaskeh, M., Guilandehi, S. N., Baghbanzadeh, A., Zand, R., Baradaran, B., & Zarei, M. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30289 · Cited by 16
“The p53 family proteins’ at- tachment into DNA was defined through the sequence of quarter sites that possibly correspond to binding to the molecules of a p53 tetramer (Cho et al., 1994).”
BackgroundAboul‐Soud, M. A. M., Siddique, R., Fozia, F., Ullah, A., Rashid, Y., Ahmad, I., Zaghloul, N. S. S., Al-Rejaie, S. S., & Mohany, M. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-27483-3 · Cited by 14
“The DNA-binding domain of gene expressions contains a complex tertiary structure that is stabilized by ZnO-NPs (Cho et al. 1994).”
BackgroundMoussa, C. E.-H. (2015) · Neurodegenerative Diseases · doi:10.1159/000430888 · Cited by 13
A Protein Turnover Signaling Motif Controls the Stimulus-Sensitivity of Stress Response Pathways
Loriaux, P. M., & Hoffmann, A. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002932 · Cited by 17
“catalyzed p53 ubiquitination [34,35], or by affecting p53’s ability to bind DNA and induce the expression of new Mdm2 [36–39].”
BackgroundMutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma
Todorova, T. A., Jordanov, S. H., Stancheva, G. S., Chalakov, I. J., Melnicharov, M. B., Kŭnev, K., Mitev, V., Kaneva, R. P., & Goranova, T. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-014-9836-0 · Cited by 13
Li, H., Wu, Z., Shen, Z., Shen, G., & Yu, R. (2013) · Nanoscale · doi:10.1039/c3nr03547f · Cited by 13
Soans, E., Evans, S. C., Cipolla, C. M., & Fernandes, E. (2014) · PubMed · Cited by 13
Anderson, C. L., Routes, T. C., Eckhardt, L. L., Delisle, B. P., January, C. T., & Kamp, T. J. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0842-1 · Cited by 13
“Structural models were created in Pymol using Protein Data Bank (PDB) ID 5K7L for EAG1, PDB: 1BYW for the PASD,13 PDB: 1IFR for the IgD,21 and PDB: 1TSR for the DBD.17 Three models (PDB 1BYW, 4HP9, 4HQA)13,23 were used as inputs for FoldX PASD calculations7 using the YASARA molecular graphics interface.”
MethodInfluentialBizzarri, A. R., & Cannistraro, S. (2021) · Cancers · doi:10.3390/cancers13236108 · Cited by 14
“The structure of the DBD portion of p53, as obtained by X-Ray, conjugated with consensus DNA (derived from 1TUP entry from Protein Data Bank (PDB) pdb [41]), is shown in Figure 1A.”
BackgroundMethodInfluentialNovel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.
Bowne, W. B., Michl, J., Bluth, M. H., et al. (2007) · PubMed · Cited by 13
Haas, M. J., & Pitot, H. C. (1998) · PubMed · Cited by 13
P53 integrity in the genetically engineered mammalian cell lines AHH-1 and MCL-5
Guest, R. D., & Parry, J. M. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(98)00223-1 · Cited by 13
p53 Interacts with RNA Polymerase II through Its Core Domain and Impairs Pol II Processivity In Vivo
Kim, S., Balakrishnan, S. K., & Gross, D. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022183 · Cited by 14
“The core domain is composed of a common immunoglobulin scaffold with a DNA-binding surface formed by a loop–sheet–helix (LSH) motif and two b-turn loops (L2 and L3) tethered by a single zinc atom [17].”
BackgroundThermodynamics of specific protein-RNA interactions.
Stolarski, R. (2003) · Acta Biochimica Polonica · doi:10.18388/abp.2003_3688 · Cited by 13
“According to a fundamental paradigm in molecular biology structure determines molecular activity in vivo (see, e.g., Cho et al., 1994).”
BackgroundIkeda, J., Tada, M., Ishii, N., Saya, H., Tsuchiya, K., Okaichi, K., Mishima, K., Sawamura, Y., Fulci, G., Liu, T.-J., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1431 · Cited by 13
Duan, W., Gao, L., Wu, X., Hade, E. M., Gao, J., Ding, H., Barsky, S. H., Otterson, G. A., & Villalona-Calero, M. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005563 · Cited by 13
Temperature-Sensitive Mutants of p53 Homologs
Pochampally, R. R., Li, C., Lu, W., Chen, L., Luftig, R. B., Lin, J., & Chen, J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4056 · Cited by 13
Chakravarty, G., Redkar, A., & Mittra, I. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.514 · Cited by 13
Mutations at Position 277 Modify the DNA-Binding Specificity of Human p53 in Vitro
Chêne, P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1294 · Cited by 13
Sauer, R. T. (1996) · Structure · doi:10.1016/s0969-2126(96)00025-1 · Cited by 13
“For example, LacI-type models in which D2-symmetric tetramerization domains are asymmetrically linked to dimeric DNA-binding domains have been proposed to explain how tetramers of both the tumor-suppressor protein p53 [14,15] and the Mnt repressor [16] bind to their DNA recognition sites.”
Jenkins, G. J. S., Morgan, C., BAXTER, J. N., Parry, E. M., & Parry, J. M. (2001) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s1383-5718(01)00281-9 · Cited by 15
Novel techniques for visualising biological information.
Robinson, A. J., & Flores, T. P. (1997) · PubMed · Cited by 13
Common Conformational Effects of p53 Mutations
Chen, J. M., Rosal, R. V., Smith, S., Pincus, M. R., & Brandt‐Rauf, P. W. (2001) · Journal of Protein Chemistry · doi:10.1023/a:1011065022283 · Cited by 14
Johnsson, N. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03533-0 · Cited by 12
Identification of TP53 Gene Mutations in Uterine Corpus Cancer with Short Follow-up
Koul, A., Borg, Å., Pejovic, T. B., et al. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4859 · Cited by 13
Takahashi, Y., Nagata, T., Asai, S., et al. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(00)00231-4 · Cited by 13
“The resulting mutation at this codon has been shown to alter p53 transcriptional activity and growth suppression [14].”
BackgroundWolkowicz, R., Peled, A., Elkind, B., & Rotter, V. (1998) · Cancer Detection and Prevention · doi:10.1046/j.1525-1500.1998.00003.x · Cited by 13
Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
Drachenberg, D., Elgamal, A. A., Rowbotham, R. K., Peterson, M. K., & Murphy, G. P. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19991001)41:2<134::aid-pros8>3.0.co;2-e · Cited by 283
Qi, Y. B., Xu, Z.-M., Shen, S., Wang, Z., & Wang, Z.-Z. (2024) · Bioessays · doi:10.1002/bies.202300209 · Cited by 5
DNA binding proteins: outline of functional classification
Zheng, Z., & Wang, Y. (2011) · BioMolecular Concepts · doi:10.1515/bmc.2011.023 · Cited by 14
(2002) · Cambridge University Press eBooks · doi:10.1017/cbo9780511815034.010 · Cited by 13
Rasquinha, J. A., Bej, A., Dutta, S., & Mukherjee, S. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00514 · Cited by 13
The ion channel TRPM7 regulates zinc-depletion-induced MDMX degradation
Wang, H., Li, B., Asha, K., Pangilinan, R. L., Thuraisamy, A., Chopra, H., Rokudai, S., Yu, Y., Prives, C. L., & Zhu, Y. Y. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101292 · Cited by 14
Antitumor Activity of Bioactive Compounds from Rapana venosa against Human Breast Cell Lines
Petrova, M., Vlahova, Z., Schröder, M., Todorova, J., Tzintzarov, A., Gospodinov, A. G., Velkova, L. G., Kaynarov, D., Dolashki, A., Dolashka, P. A., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020181 · Cited by 15
“In response to stress, cytoplasmic p53 is activated and stabilized and accumulates in the nucleus, where it activates gene transcription and triggers growth arrest or apoptosis [44].”
BackgroundOPUS-Mut: Studying the Effect of Protein Mutation through Side-Chain Modeling
Xu, G., Wang, Q., & Ma, J. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c00847 · Cited by 12
Dipeptide analysis of p53 mutations and evolution of p53 family proteins
Huang, Q., Yu, L., Levine, A. J., Nussinov, R., & Ma, B. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.04.002 · Cited by 11
“destabilization of p53, often affecting p53-DNA interactions [17, 18], others are still not entirely understood.”
Water’s potential role: Insights from studies of the p53 core domain
Xu, X. J., Ma, Z., Wang, X., Xiao, Z., Li, Y., Xue, Z. H., & Wang, Y. H. (2011) · Journal of Structural Biology · doi:10.1016/j.jsb.2011.12.008 · Cited by 12
Combined Loss of EAF2 and p53 Induces Prostate Carcinogenesis in Male Mice
Wang, Y., Pascal, L. E., Zhong, M., Ai, J., Wang, D., Jing, Y., Pilch, J., Song, Q., Rigatti, L. H., Graham, L., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00409 · Cited by 13
“(1)] in which the p53 protein loses the ability to bind DNA and activate transcription of p53 target genes (2).”
BackgroundAllosteric Modulation of Intrinsically Disordered Proteins
Rehman, A. U., Rahman, M. U., Arshad, T., & Chen, H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_14 · Cited by 12
Heterogeneous genomic aberrations in esophageal squamous cell carcinoma: a review.
Li, R., Li, P., Xing, W., & Qiu, H. (2020) · PubMed · Cited by 14
Structure of the p53/RNA polymerase II assembly
Liou, S.-H., Singh, S. K., Singer, R. H., Coleman, R. A., & Liu, W.-L. (2021) · Communications Biology · doi:10.1038/s42003-021-01934-4 · Cited by 12
Soonnarong, R., Tungsukruthai, S., Nutho, B., Rungrotmongkol, T., Vinayanuwattikun, C., Maluangnont, T., & Pithi Chanvorachote, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081233 · Cited by 13
“The planar surface and functional motifs of such 2D inorganic nanosheets can be modified using a surface engineering process involving chemical bonding or physical adsorption [22], which facilitates applications in physiological environments, through, e.”
BackgroundMethodHan, I. S. M., Abramson, D. I., & Thayer, K. M. (2022) · ACS Omega · doi:10.1021/acsomega.1c05624 · Cited by 14
“0 and 16.0 simulation packages and AMBERTOOLS14 suite.18 FF14SB force fields for the protein19 and the TIP3P potential for solvent water were used.20,21 p53 DBD starting configurations of the WT (PDB ID:1TUP, Cho et al, 1994) and Y220C + PK11000 (PDB ID: 5LAP, Bauer et al. 2016) systems were obtained from the Protein…”
MethodInfluentialCachot, J., Chérel, Y., Galgani, F., & Vincent-Hubert, F. (2000) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s1383-5718(99)00205-3 · Cited by 12
Mutation and expression of the p53 gene during chemical hepatocarcinogenesis in F344 rats
Fu, Y., Deng, W., Kawarada, Y., et al. (2003) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(03)00113-1 · Cited by 12
Comprehensive Cancer Centres and the war on cancer
Nathan, D. G., & Benz, E. J. J. (2001) · Nature reviews. Cancer · doi:10.1038/35106102 · Cited by 12
QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants
Koulgi, S., Achalere, A., Sharma, N., Sonavane, U., & Joshi, R. (2013) · Journal of Molecular Modeling · doi:10.1007/s00894-013-2042-2 · Cited by 11
The p53 Tumour Suppressor Protein
Hickman, E. S., & Helin, K. (2000) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2000.10647992 · Cited by 13
A Single Mutant, A276S of p53, Turns the Switch to Apoptosis
Reaz, S., Mossalam, M., Okal, A., & Lim, C. S. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300598k · Cited by 12
DNA (cytosine-5)-methyltransferase 1 as a mediator of mutant p53-determined p16ink4A down-regulation
Guo, Z., Tsai, M., Shiao, Y., Chen, L., Wei, M.-L., Lv, X., Gius, D. R., Little, J. B., Mitchell, J. B., & Chuang, E. Y.-Y. (2007) · Journal of Biomedical Science · doi:10.1007/s11373-007-9222-y · Cited by 12
“p53 has three functional domains and the majority of mutations occur in the core DNA-binding region (codons 102–292) which contains sequence-specific DNA affinity [ 20 ].”
BackgroundJohnson, D. G., Coleman, A., Powell, K. L., & MacLeod, M. C. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199710)20:2<216::aid-mc8>3.0.co;2-k · Cited by 12
Kusewitt, D. F., Sherburn, T. E., Miska, K. B., Tafoya, G. B., Gale, J. M., & Miller, R. D. (1999) · Carcinogenesis · doi:10.1093/carcin/20.6.963 · Cited by 11
Radiosensitization and DNA repair inhibition by pentoxifylline in NIH3T3 p53 transfectants
Binder, A. B., Theron, T., Donninger, H., Parker, M., & Böhm, L. (2002) · International Journal of Radiation Biology · doi:10.1080/0955300021000016369 · Cited by 12
“In the p53 frameshift mutant p53-DA loop–sheet–helix motif (Cho et al. 1994) .”
BackgroundLee, H., Li, D., Prior, T., et al. (1997) · Cell Biology and Toxicology · doi:10.1023/a:1007419810705 · Cited by 12
Base eversion and shuffling by DNA methyltransferases
Nelsons, H. C. M., & Bestor, T. H. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90089-7 · Cited by 12
CMV-p53 Interaction May Help Explain Clogged Arteries
Marx, J. L. (1994) · Science · doi:10.1126/science.8023154 · Cited by 12
OPUS-Mut: studying the effect of protein mutation through side-chain modeling
Xu, G., Wang, Q., & Ma, J. (2022) · doi:10.1101/2022.05.10.491420 · Cited by 12
Target-binding behavior of IDPs via pre-structured motifs
Kim, D.-H., & Han, K. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.07.031 · Cited by 12
Complete Models of p53 Better Inform the Impact of Hotspot Mutations
Solares, M. J., & Kelly, D. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315267 · Cited by 12
“Two hotspots have been determined to have this ability: R273H (Movie S7) and R248W (Movie S8) [26,42].”
BackgroundInfluentialAnticancer therapeutic strategies for targeting mutant p53-Y220C
Chasov, V. V., Davletshin, D., Gilyazova, E., Mirgayazova, R., Kudriaeva, A. A., Khadiullina, R., Yuan, Y., & Bulatov, E. (2023) · Journal of Biomedical Research · doi:10.7555/jbr.37.20230093 · Cited by 14
Al‐Otaibi, W. A., AlMotwaa, S. M., Abubakr, A. S., Hassan, S. S., & Rashidi, F. B. (2025) · Applied Organometallic Chemistry · doi:10.1002/aoc.70000 · Cited by 12
Thapar, R. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.02.006 · Cited by 10
“Proteins such as the zinc finger containing protein TFIIIA from Xenopus [121,122], human p53 [123,124], the Wilms”
BackgroundThree optimized assays for the evaluation of compounds that can rescue p53 mutants
Wu, J., Song, H., Wang, Z., & Lu, M. M. (2021) · STAR Protocols · doi:10.1016/j.xpro.2021.100688 · Cited by 12
“We speculate that this is because of the DBD topology (i.e., strand 10 connecting a loop in the vicinity of the PAb1620 epitope to the C-terminal helix).”
BackgroundInfluentialLiu, X., Ge, Z., Yang, F., Contreras, A., Lee, S., White, J. B., Lu, Y., Labrie, M., Arun, B., Moulder, S. L., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00427-9 · Cited by 15
Zhang, X., Ding, B., Chen, L., et al. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-2627 · Cited by 11
“Transl Cancer Res 2022;11(6):1844-1849 | https://dx.doi.org/10.21037/tcr-21-2627 non-small cell lung cancer (NSCLC) (7-9).”
InfluentialTherapeutic strategies for head and neck cancer based on p53 status
Ota, I., Okamoto, N., Yane, K., Takahashi, A., Masui, T., Hosoi, H., & Ohnishi, T. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.474 · Cited by 11
“One of the significant features of p53 tumor-suppressor activity is its ability to bind to p53CON; the majority of mutations in p53 are localized in the binding domain of p53CON (60,61).”
Berge, E. O., Huun, J., Lillehaug, J. R., Lønning, P. E., & Knappskog, S. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.12.004 · Cited by 14
p53 R175H hydrophobic patch and H ‐bond reorganization observed by MD simulation
Thayer, K. M., & Quinn, T. R. (2015) · Biopolymers · doi:10.1002/bip.22766 · Cited by 11
ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation
Morton, D. J., Patel, D., Joshi, J., Hunt, A., Knowell, A. E., & Chaudhary, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13701 · Cited by 11
“Mutant p53 can be classified into two groups: type I mutations, which affect amino acid residues directly involved in the DNA interaction (R248H, V274F, and R273H), and class II mutations involving residues responsible for stabilization of the three-dimensional structure of p53 [1, 11].”
BackgroundPorubiaková, O., Bohálová, N., Inga, A., Vadovičová, N., Coufal, J., Fojta, M., & Brázda, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010127 · Cited by 13
“and histidines that coordinate Zn2+ or Mg2+ ions, which are essential for FLp53α conformation and DNA-binding activity [9].”
BackgroundMolecular mechanisms of functional rescue mediated by P53 tumor suppressor mutations
Tan, Y.-H., Chen, Y. M., Ye, X. Y., Lü, Q., Tretyachenko-Ladokhina, V., Yang, W. Y., Senear, D. F., & Luo, R. (2009) · Biophysical Chemistry · doi:10.1016/j.bpc.2009.08.008 · Cited by 11
“The atomic coordinates of the wild type p53 DBD were obtained from crystal structure 1TSR chain B [13].”
Ichikawa, W., Ooyama, A., Toda, E., Sugimoto, Y., Oka, T., Takahashi, T., Shimizu, M., Sasaki, Y., & Hirayama, R. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0217-6 · Cited by 15
“The majority of mutations (12/ 28; 43%) was found within the “hotspot” codons 175, 245, 248, and 273, between exon 4 and 9, which are highly conserved throughout evolution and contain the DNA binding domain of the protein essential to p53 functional activity [5].”
BackgroundInfluentialStereolithographic models of biopolymers
Yourtee, D. M., Emery, J. D., Smith, R. E., et al. (2000) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(00)00029-2 · Cited by 11
Kamata, H., Mitani, S., Fujiwara, M., Aoki, N., Okada, S., & Mori, S. (2007) · Clinical and Experimental Medicine · doi:10.1007/s10238-007-0124-0 · Cited by 12
“Arg 273 is directly involved in phosphate-backbone contact in the major groove of the DNA helix [31].”
BackgroundZelazny, E. T., Li, B., Anagnostopoulos, A.-M., Coleman, A., & Perkins, A. S. (2001) · Experimental and Molecular Pathology · doi:10.1006/exmp.2001.2357 · Cited by 11
(1-Benzimidazolonyl)alanine (Bia): preliminary investigations into a potential tryptophan mimetic
Huber, V. J., Arroll, T. W., Lum, C., Goodman, B. A., & Nakanishi, H. (2002) · Tetrahedron Letters · doi:10.1016/s0040-4039(02)01501-0 · Cited by 11
p53 – ein natürlicher Krebskiller: Einsichten in die Struktur und Therapiekonzepte
Römer, L., Klein, C., Dehner, A., Kessler, H., & Büchner, J. (2006) · Angewandte Chemie · doi:10.1002/ange.200600611 · Cited by 16
Zinc Finger Interactions with Metals and Other Small Molecules
Hanas, J. S., Larabee, J. L., & Hocker, J. R. S. (2005) · Springer eBooks · doi:10.1007/0-387-27421-9_8 · Cited by 11
Potential role ofp53 mutation in chemical hepatocarcinogenesis of rats
Deng, W., Fu, Y., Li, Y., et al. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i1.46 · Cited by 11
Mechanisms of p53 activation and physiological relevance in the developing kidney
Aboudehen, K., Hilliard, S. A., Saifudeen, Z. R., & El-Dahr, S. S. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00642.2011 · Cited by 12
“Hot spot mutations found in 50% of human cancer are for the most part located in the DNA-binding domain (12).”
BackgroundBabikir, H. A., Afjei, R., Paulmurugan, R., & Massoud, T. F. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.004 · Cited by 11
Malami, I., Muhammad, A. I., Etti, I. C., Waziri, P. M., & Alhassan, A. M. (2017) · EXCLI journal · doi:10.17179/excli2017-299 · Cited by 12
“The basis of DNA structural recognition by wild-type p53 implicates residues mainly from the L1 loop, H2 helix, L3 loop, and DNA phosphate from the minor and major groove of p53 DNA-binding core domain (Cho et al., 1994; Kitayner et al., 2006).”
BackgroundDerbyshire, D. J., Basu, B. P., Date, T., Iwabuchi, K., & Doherty, A. J. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902010910 · Cited by 10
“The core-domain structure of p53 (Cho et al., 1994) has been successfully positioned into the complex structure and there is clear evidence for the position of 53BP1.”
BackgroundMethodGenetic Alterations in Human Tumors
Cho, K. R., & Hedrick, L. (1997) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-60505-5_7 · Cited by 9
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.